Physician profile
Esther Tan
NPI 1982754487
$7,979.50
in general payments reported to CMS, 2019-2025
47 companies · $1,752 in 2025
The $1,752 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $363 · 2021: $1,029 · 2022: $1,828 · 2023: $1,007 · 2024: $1,478 · 2025: $1,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,250 · Food and Beverage: $1,898 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,249.91 |
| Food and Beverage | $1,898.35 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,333.67 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $1,010.00 | 2022 | |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $296.01 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $248.16 | 2019-2025 | Tagrisso, Enhertu, Calquence |
| Amgen INC. | $232.42 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $207.15 | 2021-2024 | Fruzaqla, Ninlaro |
| Janssen Biotech, INC. | $197.58 | 2021-2025 | Tecvayli, Darzalex, Erleada |
| Merck Sharp & Dohme LLC | $170.68 | 2021-2025 | Keytruda, Keytruda Qlex, Welireg |
| Gilead Sciences, INC. | $163.64 | 2021-2025 | Trodelvy |
| Seagen INC. | $135.64 | 2019-2023 | Adcetris, Padcev |
| Intuitive Surgical, INC. | $132.49 | 2025 | |
| Boston Scientific Corporation | $124.99 | 2020 | |
| Glaxosmithkline, LLC. | $116.54 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Veran Medical Technologies, INC. | $92.27 | 2019 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $89.95 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $89.69 | 2022-2025 | Libtayo |
| Genentech USA, INC. | $83.25 | 2019-2024 | Phesgo, Polivy, Itovebi |
| Eisai INC. | $75.95 | 2019-2025 | |
| Pfizer INC. | $71.75 | 2019-2024 | |
| Lilly USA, LLC | $57.28 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Taiho Oncology, INC. | $51.75 | 2019-2024 | |
| Inari Medical, INC. | $51.01 | 2020 | |
| Celgene Corporation | $43.66 | 2019-2023 | Reblozyl |
| Exelixis INC. | $42.48 | 2019-2025 | Cabometyx |
| Caris Mpi, INC. | $40.87 | 2025 | Mi Cancer Seek |
| Astellas Pharma US INC | $37.31 | 2020-2025 | Vyloy |
| Incyte Corporation | $35.70 | 2021-2023 | Jakafi |
| Medtronic, INC. | $33.75 | 2022 | |
| Abbvie INC. | $30.81 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.69 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $27.58 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.74 | 2021 | |
| Sobi, INC | $22.72 | 2025 | |
| Alexion Pharmaceuticals, INC. | $22.51 | 2019 | |
| Kite Pharma, INC. | $22.47 | 2019 | |
| Blueprint Medicines Corporation | $22.27 | 2024 | Ayvakit |
| Karyopharm Therapeutics INC. | $20.77 | 2023 | Xpovio |
| Beone Medicines USA, INC. | $19.61 | 2025 | Brukinsa |
| Myriad Genetic Laboratories, INC. | $19.39 | 2023 | Precisetumor |
| Stemline Therapeutics INC. | $18.64 | 2023 | Orserdu |
| Tesaro, INC. | $17.33 | 2019 | |
| Array Biopharma INC | $14.21 | 2022 | |
| Servier Pharmaceuticals LLC | $13.92 | 2022 | |
| Rigel Pharmaceuticals, INC. | $13.77 | 2023 | Rezlidhia, Tavalisse |
| Mirati Therapeutics, INC. | $12.97 | 2023 | Krazati |
| Clovis Oncology, INC. | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esther Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.